341 related articles for article (PubMed ID: 27776339)
41. A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy.
Meeuwsen MH; Wouters AK; Jahn L; Hagedoorn RS; Kester MGD; Remst DFG; Morton LT; van der Steen DM; Kweekel C; de Ru AH; Griffioen M; van Veelen PA; Falkenburg JHF; Heemskerk MHM
Mol Ther; 2022 Feb; 30(2):564-578. PubMed ID: 34371177
[TBL] [Abstract][Full Text] [Related]
42. Nanobody Based Dual Specific CARs.
De Munter S; Ingels J; Goetgeluk G; Bonte S; Pille M; Weening K; Kerre T; Abken H; Vandekerckhove B
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385713
[TBL] [Abstract][Full Text] [Related]
43. The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies.
Markovič T; Podgornik H; Avsec D; Nabergoj S; Mlinarič-Raščan I
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163524
[TBL] [Abstract][Full Text] [Related]
44. Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H.
Inaguma Y; Akahori Y; Murayama Y; Shiraishi K; Tsuzuki-Iba S; Endoh A; Tsujikawa J; Demachi-Okamura A; Hiramatsu K; Saji H; Yamamoto Y; Yamamoto N; Nishimura Y; Takahashi T; Kuzushima K; Emi N; Akatsuka Y
Gene Ther; 2014 Jun; 21(6):575-84. PubMed ID: 24694533
[TBL] [Abstract][Full Text] [Related]
45. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.
Palomba ML; Roberts WK; Dao T; Manukian G; Guevara-Patiño JA; Wolchok JD; Scheinberg DA; Houghton AN
Clin Cancer Res; 2005 Jan; 11(1):370-9. PubMed ID: 15671568
[TBL] [Abstract][Full Text] [Related]
46. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient.
Knutson KL; Disis ML
Hum Immunol; 2002 Jul; 63(7):547-57. PubMed ID: 12072190
[TBL] [Abstract][Full Text] [Related]
47. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.
Vera J; Savoldo B; Vigouroux S; Biagi E; Pule M; Rossig C; Wu J; Heslop HE; Rooney CM; Brenner MK; Dotti G
Blood; 2006 Dec; 108(12):3890-7. PubMed ID: 16926291
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells.
Klar R; Schober S; Rami M; Mall S; Merl J; Hauck SM; Ueffing M; Admon A; Slotta-Huspenina J; Schwaiger M; Stevanović S; Oostendorp RA; Busch DH; Peschel C; Krackhardt AM
Leukemia; 2014 Dec; 28(12):2355-66. PubMed ID: 24736212
[TBL] [Abstract][Full Text] [Related]
49. Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody.
Bernardeau K; Gouard S; David G; Ruellan AL; Devys A; Barbet J; Bonneville M; Chérel M; Davodeau F
Eur J Immunol; 2005 Oct; 35(10):2864-75. PubMed ID: 16163672
[TBL] [Abstract][Full Text] [Related]
50. Engineering improved T cell receptors using an alanine-scan guided T cell display selection system.
Malecek K; Zhong S; McGary K; Yu C; Huang K; Johnson LA; Rosenberg SA; Krogsgaard M
J Immunol Methods; 2013 Jun; 392(1-2):1-11. PubMed ID: 23500145
[TBL] [Abstract][Full Text] [Related]
51. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.
Weng J; Rawal S; Chu F; Park HJ; Sharma R; Delgado DA; Fayad L; Fanale M; Romaguera J; Luong A; Kwak LW; Neelapu SS
Blood; 2012 Aug; 120(8):1613-23. PubMed ID: 22645177
[TBL] [Abstract][Full Text] [Related]
52. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
53. WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
van Amerongen RA; Hagedoorn RS; Remst DFG; Assendelft DC; van der Steen DM; Wouters AK; van de Meent M; Kester MGD; de Ru AH; Griffioen M; van Veelen PA; Falkenburg JHF; Heemskerk MHM
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728869
[TBL] [Abstract][Full Text] [Related]
54. Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.
James SE; Orgun NN; Tedder TF; Shlomchik MJ; Jensen MC; Lin Y; Greenberg PD; Press OW
Blood; 2009 Dec; 114(27):5454-63. PubMed ID: 19880489
[TBL] [Abstract][Full Text] [Related]
55. Single T cell receptor-mediated recognition of an identical HIV-derived peptide presented by multiple HLA class I molecules.
Ueno T; Tomiyama H; Takiguchi M
J Immunol; 2002 Nov; 169(9):4961-9. PubMed ID: 12391209
[TBL] [Abstract][Full Text] [Related]
56. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
[TBL] [Abstract][Full Text] [Related]
57. PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
van Amerongen RA; Tuit S; Wouters AK; van de Meent M; Siekman SL; Meeuwsen MH; Wachsmann TLA; Remst DFG; Hagedoorn RS; van der Steen DM; de Ru AH; Verdegaal EME; van Veelen PA; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2023; 14():1121973. PubMed ID: 37026005
[TBL] [Abstract][Full Text] [Related]
58. Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex.
Hoffmann TK; Donnenberg VS; Friebe-Hoffmann U; Meyer EM; Rinaldo CR; DeLeo AB; Whiteside TL; Donnenberg AD
Cytometry; 2000 Dec; 41(4):321-8. PubMed ID: 11084618
[TBL] [Abstract][Full Text] [Related]
59. HLA-DPB1 Reactive T Cell Receptors for Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation.
Klobuch S; Hammon K; Vatter-Leising S; Neidlinger E; Zwerger M; Wandel A; Neuber LM; Heilmeier B; Fichtner R; Mirbeth C; Herr W; Thomas S
Cells; 2020 May; 9(5):. PubMed ID: 32443793
[TBL] [Abstract][Full Text] [Related]
60. Mixed functional characteristics correlating with TCR-ligand koff -rate of MHC-tetramer reactive T cells within the naive T-cell repertoire.
Hombrink P; Raz Y; Kester MG; de Boer R; Weißbrich B; von dem Borne PA; Busch DH; Schumacher TN; Falkenburg JH; Heemskerk MH
Eur J Immunol; 2013 Nov; 43(11):3038-50. PubMed ID: 23893393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]